PL37

Ligand id: 7896

Name: PL37

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 20
Topological polar surface area 192.85
Molecular weight 518.16
XLogP 6.12
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
IUPAC Name
1-ethoxycarbonyloxyethyl 2-[[2-[(2-amino-4-methylsulfanylbutyl)disulfanylmethyl]-3-phenylpropanoyl]amino]acetate
Synonyms
19-IIIa [3] | Debio 0827 [1] | Debio-0827
Database Links
PubChem CID 16123252
Search Google for chemical match using the InChIKey BJCNUZJDFWFVBY-UHFFFAOYSA-N
Search Google for chemicals with the same backbone BJCNUZJDFWFVBY
Search UniChem for chemical match using the InChIKey BJCNUZJDFWFVBY-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone BJCNUZJDFWFVBY
Comments
PL37 is an investigational, orally available, dual pro-drug inhibitor of neprilysin (a.k.a. neutral endopeptidase or NEP; MME) and aminopeptidase N (APN; ANPEP) [3]. NEP and APN are enkephalin catabolising enzymes (or enkephalinases). Dual ENKephalinase inhibitors such as this one have been ascribed the acronym DENK inhibitor (or DENKi).
PL37 is the non-stereo enantiomer of compound 15 in patent US8247609 [4]. Such dual inhibitors are suggested as a novel mechanism for the control of central and peripheral pain [5], via inhibition of enzymatic degradation of endogenous enkephalins. Such agents could replace the use of opiate analgesics.